FDA Setback for Outlook Therapeutics’ ONS-5010
The FDA asks for more proof, pushing Outlook’s ophthalmic bevacizumab ambitions back into review mode. Another lap around the regulatory…
SeaBeLife and Unither Partner to Advance SBL03 for Dry AMD and GA
Two companies, one goal: speed SBL03 toward trials in diseases that need new answers. SeaBeLife (Roscoff, France) has inked a…
popular posts
latest posts
